| 000 | 01843 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250517144807.0 | ||
| 264 | 0 | _c20180521 | |
| 008 | 201805s 0 0 eng d | ||
| 022 | _a1938-0682 | ||
| 024 | 7 |
_a10.1016/j.clgc.2017.02.007 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAlumkal, Joshi J | |
| 245 | 0 | 0 |
_aEffect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. _h[electronic resource] |
| 260 |
_bClinical genitourinary cancer _c10 2017 |
||
| 300 |
_a610-617.e3 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLiver Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aNitriles |
| 650 | 0 | 4 |
_aPhenylthiohydantoin _xadministration & dosage |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aProstatic Neoplasms, Castration-Resistant _xdrug therapy |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aChowdhury, Simon | |
| 700 | 1 | _aLoriot, Yohann | |
| 700 | 1 | _aSternberg, Cora N | |
| 700 | 1 | _ade Bono, Johann S | |
| 700 | 1 | _aTombal, Bertrand | |
| 700 | 1 | _aCarles, Joan | |
| 700 | 1 | _aFlaig, Thomas W | |
| 700 | 1 | _aDorff, Tanya B | |
| 700 | 1 | _aPhung, De | |
| 700 | 1 | _aForer, David | |
| 700 | 1 | _aNoonberg, Sarah B | |
| 700 | 1 | _aMansbach, Hank | |
| 700 | 1 | _aBeer, Tomasz M | |
| 700 | 1 | _aHigano, Celestia S | |
| 773 | 0 |
_tClinical genitourinary cancer _gvol. 15 _gno. 5 _gp. 610-617.e3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.clgc.2017.02.007 _zAvailable from publisher's website |
| 999 |
_c27017148 _d27017148 |
||